“…The cost-effectiveness of CML treatment has been of particular interest for physicians and researchers in many countries. [8][9][10][11] As a solution to this problem, Padula et al compared the costeffectiveness of an "imatinib-first" approach, in which physicians start treatment with imatinib, switching to dasatinib or nilotinib only in cases of resistance or intolerance, to that of a "physician's choice" approach, in which they initiate treatment with any 1 of 3 TKIs. 8 Their Markov model analysis clearly showed that the imatinib-first approach was associated with lower cost but similar quality-adjusted life years (QALYs) compared with the physician's choice approach.…”